TB constitutes a public health problem at a global level. It’s essential that professionals are well aware of the strategies and solutions for the challenges that TB entails. The End TB Strategy by the WHO calls on governments to commit to the adaptation and implementation of this strategy, relying not only on the health sector, but seeking to comprise a multisectorial effort that’s able to end TB on a global scale.
Educational aims
- Build knowledge of healthcare professionals and other professionals on epidemiological traits of TB on a global scale;
- Have the confidence to devise and develop strategies that are able to lessen the burden of TB;
- Understand the premises and topics underlying the End TB Strategy and which efforts could be undertaken in order to compromise with the targets established by the WHO
Topics/Programme
- Epidemiology of TB (estimates of incidence, mortality, drug-resistant TB estimates, TB/HIV);
- International targets and progress towards them;
- New challenges and strategies to move forward;
- Global End TB Strategy to face the challenge;
- Q&A
Following the webinar, participants will be able to:
- Understand the global impact of TB, through epidemiological concepts;
- Transpose epidemiological concepts of TB to clinical practice;
- Understand the global challenges of TB;
- Develop strategies that will allow to lessen the burden of TB;
- Understand the premises underlying the End TB Strategy and its implications for clinical practice.
Format
Panel discussion divided into two parts (of approximately 30 min each):
- Presentation on the global burden of TB (Mario Raviglione)
- Open discussion and Q&A (moderated by chairs)
UNITE4TB is a public-private partnership with representation from academic institutions, small- and medium-sized enterprises (SMEs), public organisations, and pharmaceutical companies. The 7-year, €185 million project aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active Tuberculosis (TB) treatment regimens for drug-resistant and -sensitive TB. For more information, visit the consortium website: unite4TB.org
The UNITE4TB project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research. For further information: imi.europa.eu
This communication reflects the author’s view. Neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.”
